The Diabetes Research Institute Foundation (DRIF) extends its heartfelt congratulations to Dr. Jay Skyler on his recent appointment to the Board of Directors at SAB Biotherapeutics (Nasdaq: SABS). This appointment marks a significant achievement for both Dr. Skyler and the ongoing mission at the Diabetes Research Institute (DRI). Dr. Skyler’s extensive expertise and leadership in type 1 diabetes research make him an invaluable addition to SAB’s board. His decades-long commitment to advancing our understanding of T1D, coupled with his vision for innovative therapies, align perfectly with SAB’s ..read more

Enhanced technique improves evaluation of islet cell transplants In recent years, there has been significant progress in treating type 1 diabetes using transplants of islet cells and stem cell-derived beta cells. These cells are crucial because they help the body produce insulin, which controls blood sugar. However, one major challenge remains: ensuring that these cells are consistently effective before they are used in patients. Traditionally, the effectiveness of these cells, often sourced from donated pancreases, has been assessed by measuring how much insulin they produce under different ..read more

Your Legacy Gift: A Catalyst for a Cure Thoughtful and generous supporters who have included the Diabetes Research Institute Foundation in their estate plans or made contributions through designated giving vehicles are the powerful sustaining heartbeat of the DRI’s research programs. The Diabetes Research Institute (DRI) Heritage Society pays tribute to these special individuals whose commitments provide a pipeline of critical funding ensuring that cure-focused research continues into the future. Many of our supporters have made substantial gifts to the DRI Foundation in ways that comple ..read more

On Thursday, February 29, 2024 the Diabetes Research Institute Foundation kicked off its Parent Series with a discussion entitled, Accelerating the Science Toward Prevention and Cure. Guests were treated to a give-and-take with leading researchers and clinicians representing the Diabetes Research Institute (DRI) and the UM Miller School of Medicine.   Special Guests: Matthias von Herrath, M.D. Scientific Director and Stacy Joy Goodman Chair Diabetes Research Institute, UM Miller School of Medicine Janine E. Sanchez, M.D. Director, Pediatric Diabetes Division of Pediatric Endocrinology UM ..read more

In February, the 16th Annual Scientific Meeting of the Network for Pancreatic Organ Donors with Diabetes (nPOD) commenced with groundbreaking discussions and a memorable tribute to a pioneer in type 1 diabetes (T1D) research. Highlighting the first day’s sessions was the George Eisenbarth Memorial Lecture, delivered by esteemed Diabetes Research Institute – University of Miami researcher, Dr. Jay Skyler. Dr. Skyler, a veteran in the field, captivated attendees with a presentation that traced four decades of T1D research, culminating in a powerful advocacy for combination therapies to combat t ..read more

In a dynamic convergence of scientific minds, the Diabetes Research Institute (DRI) recently hosted a pivotal gathering of experts in the field of diabetes research who form its Scientific Advisory Board (SAB). The SAB, appointed through collaboration between the DRI Foundation and University of Miami leadership, plays a crucial role in evaluating DRI research programs, assessing progress, and offering guidance The SAB undertook a comprehensive review, evaluating a total of 25 projects presented by 19 investigators from within the DRI. These projects spanned diverse areas of inquiry, includin ..read more

The post In Memory of Gary Kleiman appeared first on DRIF ..read more

NABTU, a long-time philanthropic partner, has raised more than $75 million since 1984 to help find a cure for type 1 diabetes. MIAMI (February 15, 2024) – The Diabetes Research Institute (DRI), a world leader in research focused on finding a cure for type 1 diabetes, and North America’s Building Trades Unions (NABTU), a long-standing and sustaining partner of the DRI, joined forces this week to unveil the NABTU Regenerative Medicine and CGMP Center at the DRI headquarters in Miami.   NABTU, a consortium of more than three million tradesmen and women across 330 local organizations, has be ..read more

The Rigor of Clinical Trials Clinical trials are the backbone of medical advancements, governed by strict regulations to ensure safety and efficacy. Before any new drug can be introduced to the public, it must undergo a rigorous testing process. This includes gaining approval for Investigational New Drugs (INDs) from the Food and Drug Administration (FDA), along with ethical clearances from relevant bodies. Only after these critical steps are thoroughly reviewed and approved can a clinical trial commence. The journey of a drug through a clinical trial involves multiple stages, focusing on saf ..read more

The post In Memory of Gary Kleiman appeared first on DRIF ..read more